

Benitec (ASX:BLT) Corporate Overview

Benitec are pioneers in the RNA interference (RNAi) field and are using proprietary technologies to develop RNAi drugs for unmet medical needs such as HIV and Hepatitis C (HCV)

In mid 2006 the new Board and advisory team commenced a strategic review to refocus the business and put together the turnaround plan to deliver improved shareholder value in 2007 and beyond.

Who are we?

- Experienced Management, Board and Advisors
- Peter Francis, Chairman, Founding Partner FAL Commercial & Technology Lawyers (Melbourne)
- Dr Mike Dalling Non Executive Director
- Dr Ken Reed Founder and Non Executive Director
- Sue MacLeman CEO
- Paul McMahon CFO and Company Secretary


Corporate Overview




- Pioneers in RNAi since 1997
- Seminal patents in DNA-directed RNA interference (ddRNAi) technology
- Multiple licensees for commercial and therapeutic uses of RNAi
- Focused on developing treatments for commercially attractive, major, life-threatening diseases
- Listed on the ASX, operations now solely in Melbourne Australia

Product Pipeline


	Development	Pre-Clinical	Clinical
Program	HIV/AIDS (stem cell)		2006
	HIV/AIDS (T-cell)		2007/08

RNAi Therapeutics- A Disruptive New Platform



 RNAi	 Small Molecules	 Antibodies
<ul style="list-style-type: none">• Target: RNA• Challenge: Delivery• Advantage: Allows facile targeting of both “druggable” and “non-druggable” regions of disease-causing genes (coding for RNA or protein)	<ul style="list-style-type: none">• Target: Protein• Challenge: Specificity• Advantage: Gold standard of treatment	<ul style="list-style-type: none">• Target: Protein• Challenge: Penetration• Advantage: Market acceptance of biotech

Mechanism of RNA interference (RNAi)



- *Natural mechanism*
- *Rapidly deployed*
- *Highly specific*
- *Catalytic*

Advantages of ddRNAi technology

Compared with alternative gene silencing technologies eg antisense and siRNA the Benitec ddRNAi technology has the following advantages:

- Lower cost and ease of preparation
- More versatile delivery options
- The ability to silence genes in whole organisms (transgenic ddRNAi)
- Ability to control the expression and timing of gene silencing

RNAi Market opportunity

- The RNAi market achieved global sales of just over USD\$1bn in 2004
- Projected to reach USD\$2.5bn by 2010
- Competitive dynamic market environment





Figure 1 Estimated annual worldwide revenues from RNAi and market segments. (a) Although the market for RNAi is new and relatively small, rapid growth has been seen and is projected to continue until 2008 as the potential is realized. (b) RNAi market segments. The size of the market reflects the time of adoption—oligonucleotides being the first method employed, followed by vector-based applications. 'Therapeutics,' which includes using RNAi for drug discovery, is relatively new. (Figure from ref. 1; courtesy of Front Line Strategic Consulting, San Mateo, CA, USA).



Market Reward for RNAi

Benitec, Alnylam, and Sirna were featured on a BIO 2006 panel discussion moderated by a Senior Analyst at Piper Jaffray as the leading companies worldwide in intellectual property and development of RNAi.


Alnylam Pharmaceuticals

- Current market cap US\$654.1MM
- In September 2005, Alnylam and Novartis formed a partnership with an up-front of US\$65MM, total deal valued at >US\$700MM


Sirna Therapeutics

- Current market cap of US\$932.2MM
- In April 2006, Sirna and GSK formed an alliance with an up-front of US\$12MM, total deal valued at >US\$700MM
- Merck purchased Sirna for 1.1B 2x market cap at the time

ALNYLAM PHARMACEUTICALS INC
as of 8-Nov-2006




SIRNA THERAPEUTIC
as of 8-Nov-2006



Intellectual Property

An industry-leading patent portfolio in RNAi



Benitec IP Position

Extract from Companies & Markets, Jain PharmaBiotech, August 2006

RNAi patents - Among the companies, Alnylam and Benitec have strong patent positions.

- On 5 June 2003, Benitec Ltd was granted its core technology patents in the US and the UK.
- These patents, with priority dating to 1998, describe a method for silencing any gene in any cell using ddRNAi.
- US Patent 6,573,099 is entitled "Genetic constructs for delaying or repressing the expression of a target gene" and UK Patent 2353282 is entitled "Control of gene expression".
- Both patents contain **world first claims** that describe the effect of RNAi in human cells and the DNA constructs which trigger RNAi.
- Benitec Ltd, originally founded in Australia in 1997 (listed on Australian Stock Exchange), pioneered ddRNAi and was the first company to demonstrate RNAi in human cells. It holds a **dominant international intellectual property position in RNAi**.

Professor Jain's report entitled "RNAi- Technologies, Companies and Markets, Jain PharmaBiotech, Basel, Switzerland, August 2006.

Licensees and Strategic Partners



- Therapeutic Use of ddRNAi
 - Tacere Therapeutics
 - Anylam Pharmaceuticals
 - CombiMatrix
 - Revivacor



- Research Reagent or Transgenic Animal Product Development and Sales
 - Sigma-Aldrich
 - genOway
 - Artemis
 - Promega
 - IDT
 - GenScript
 - Ambion




- Research Freedom to Operate
 - Merck
- Strategic Cross-Licensing
 - Anylam Pharmaceuticals
 - CombiMatrix



Benitec Capital Structure

- Shares outstanding 188.47 M
- Share price as of 17 Nov 2006 A\$0.073
- Market capitalization A\$13.75M

- Options/warrants outstanding 59.8M
- Fully diluted shares 232.5M




RNAi Drug Development Strategy

Sequence-based, broad specificity therapeutics

- Select RNAi targets quickly to cover most of patient population (RNAi advantage over small molecule)

Prevent generation of drug-resistant diseases

- Combination of multiple drugs in a single treatment (ddRNAi advantage)



Tissue-specific RNAi delivery

- Clinically relevant, previously tested viral and non-viral methods


HIV/AIDS Stem Cell Program

- Molecular Targets
 - HIV genome
 - cell-surface receptor
 - replication machinery
- Data published in *Nature Reviews*, *PNAS*, and *Molecular Therapy*
- Clinical Development Partner: City of Hope
 - Principal Investigator: John Rossi, Ph.D.
 - Clinical Investigator: John Zaia, M.D.
 - GMP mfg and stem cell transduction: Larry Couture, Ph.D.
- In Clinic: Q4 2006

HIV Program- Path to Clinic


- Stem Cell Therapy For HIV/AIDS Lymphoma
 - HIV/AIDS Lymphoma manufactured at City of Hope
 - RAC submission reviewed at the NIH on 21 September 2005
 - Pre-IND meeting held on 17 October 2005
 - Single site Phase 1 trial to be performed at the City of Hope Medical Center commencing in Q4 2006
- T-Cell Therapy for HIV/AIDS
 - Benitec, City of Hope, Fred Hutchinson Cancer Research Center, Colorado State University, and U Penn have received a US\$7.5M NIH grant for advancing the same therapy for T-cell transduction
 - Funds will cover development up to conclusion of Phase I
 - Recent inclusion of selective marker into clinical vector has achieved protection of >80% of T-cells from HIV infection in macaques

AIDS / lymphoma clinical trial design



HCV Program

- Molecular Target: Hepatitis C Virus genome
- Data published in *Nature* and *Nature Biotech*
- RNAi Therapeutics
 - Multi-targeting to prevent viral escape
 - “Cocktail” in one drug
- Licensed to Tacere Therapeutics Inc Sept 06



Recovery plan for 2006

- Refocus business with move to lower cost model of value creation with co-investment and/or licensing to bring in additional revenues
- Complete a successful capital raising to fund turnaround
- Re-establish presence in Australia and appoint Australian based management team
- Commence Phase 1 clinical trial for HIV/AIDS Lymphoma drug
- Continue out-licensing intellectual property for target validation and therapeutics
- Further strengthen our shareholder base worldwide


Risk and Mitigation

- **Risks**
 - UPSTO re-examination and Nucleonic litigation
 - Cash position
- **Mitigation**
 - Capital raising
 - Low cost model
 - Continuing to seek advice from patent attorneys and provide input to ensure the strategy for prosecution of the core ddRNAi patent applications optimizes the breadth and scope of the patent claims
 - Submitting patent applications to protect the outcome of research activities to strengthen and expand the Benitec intellectual property
 - Submitting new patent applications to protect novel product candidates and their clinical applications
 - Undertaking extensive scientific and commercial assessments of the disease targets of interest with experts in the relevant fields

Compelling opportunity for investment

- Opportunity for investors – dynamic area
 - Undervalued
 - Nobel Prize Fire and Mello – validation of science
 - Merck purchase of Sirna for 1.1B 2x market cap – validation by business
- Strong IP position
 - Global rights to human therapeutics
- High profile license deals and collaborations
- Opportunity for more deals and collaborations to bring in significant revenue
- Low cost model
- Experienced New Board, management and advisors

Benitec has the ability and opportunity to be the market leader in the development of this entirely new class of drugs



Thank you

Sue MacLeman
Level 16, 356 Collins St
Melbourne Vic 3000
+61 3 437211200
smacleman@benitec.com

www.benitec.com